3.44
+0.155(+4.72%)
Currency In USD
Address
3013 Science Park Road
San Diego, CA 92121
United States of America
Phone
858 684 1300
Website
Sector
Healthcare
Industry
Biotechnology
Employees
144
First IPO Date
February 08, 2019
| Name | Title | Pay | Year Born |
| Faheem Hasnain | Co-Founder, Chief Executive Officer, President & Chairman | 961,995 | 1958 |
| Christian Waage | Executive Vice President of Technical Operations & Administration | 583,156 | 1967 |
| Richard Aranda | Chief Medical Officer | 677,492 | 1960 |
| Bryan Giraudo | Chief Operating Officer & Chief Financial Officer | 739,622 | 1975 |
| Robert F. Roscigno | Senior Vice President of Clinical Development of Pulmonary Vascular Disease | 0 | 1966 |
| Jeff Boerneke | General Counsel & Secretary | 0 | N/A |
| Matt Cravets | Senior Vice President of Biometrics | 0 | N/A |
| Caryn L. Peterson | Executive Vice President of Regulatory Affairs | 0 | 1959 |
| Deanna Weber | Executive Vice President of Human Resources | 0 | N/A |
| Jeanine Anthony | Senior Vice President of Marketing | 0 | N/A |
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.